Active Solicitation · DEPT OF DEFENSE
AI Summary
The Defense Health Agency is seeking to develop and manage a biologic product, Dimethyl Sulfoxide Cryopreserved Platelets, aimed at enhancing the readiness of active-duty personnel. This product offers a longer shelf life compared to traditional liquid stored platelets. Interested parties are encouraged to respond to this sources sought notice.
Defense Health Agency seeks to develop and manage medical materiel to protect and sustain the Warfighter on point for the Nation. We develop, directly through collaboration with commercial partners, medical products that enhance readiness and improve the quality of life of active-duty personnel in the operational environment. OPMED’s WPAC PMO has been developing a biologic product: Dimethyl Sulfoxide (DMSO) Cryopreserved Platelets (CPP), a frozen, biologic-platelet product. DMSO CPP are formulated to provide a platelet-derived product with a longer shelf life (2 years and potentially longer) than liquid stored platelets (LSP), which are currently licensed for storage up to 5-7 days at room temperature (20ºC to 24ºC) under gentle agitation.
CRYOPRESERVED PLATELETS (CPP) FOR US FDA LICENSURE is a federal acquisition solicitation issued by DEPT OF DEFENSE. Review the full description, attachments, and submission requirements on SamSearch before the response deadline.
SamSearch Platform
AI-powered intelligence for the right opportunities, the right leads, and the right time.